Cimicifuga and Melbrosia lack oestrogenic effects in mice and rats

Einer‐Jensen, N.; Zhao, Jiang; Andersen, Kirstin; Kristoffersen, K.

doi:10.1016/0378-5122(96)01052-3

Cited by 79 publications

(35 citation statements)

References 4 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…An early animal study of Cimicifuga preparations on the uterus of mice 60 suggests that the herb does not adversely affect this organ. Likewise, a study on the uterine growth of immature mice and proliferation of the vaginal epithelium of ovariectomized rats 61 supports the notion that Cimicifuga extracts do not exert estrogenic effects. In this study, a large dose of ethanolic Cimicifuga (600 mg/kg) Similarly, a recent study 62 of ovariectomized SpragueDawley rats with 7,12-dimethylbenz[␣]anthraceneinduced mammary gland tumors shows that, unlike estrogen, Cimicifuga extract-in doses comparable to 1, 10, or 100 times the human therapeutic dosage-fails to induce mammary tumor development.…”

Section: T Low Dog Et Alsupporting

confidence: 49%

Critical evaluation of the safety of Cimicifuga racemosa in menopause symptom relief

2003

View full text Add to dashboard Cite

Objective: This comprehensive review examines the safety of Cimicifuga racemosa for the treatment of menopause symptoms, particularly in populations in which conventional menopause treatment regimens, including estrogen replacement, are contraindicated.Design: An extensive database of information on Cimicifuga, which included all published literature pertaining to preclinical and clinical safety of various forms of Cimicifuga, the FDA and World Health Organization adverse-event reporting systems, monographs, compendia, internal unpublished data from a major manufacturer, foreign literature, and historical anecdotal reports, was reviewed, and findings pertaining to the safety of Cimicifuga use for menopause treatment were reported.Results: Uncontrolled reports, postmarketing surveillance, and human clinical trials of more than 2,800 patients demonstrate a low incidence of adverse events (5.4%). Of the reported adverse events, 97% were minor and did not result in discontinuation of therapy, and the only severe events were not attributed to Cimicifuga treatment.Conclusions: Although the effects of Cimicifuga may be dependent on the specific extract preparation, this review clearly supports the safety of specific Cimicifuga extracts, particularly isopropanolic preparations, for use in women experiencing menopausal symptoms and as a safe alternative for women in whom estrogen therapy is contraindicated.

show abstract

Section: T Low Dog Et Alsupporting

confidence: 49%

Critical evaluation of the safety of Cimicifuga racemosa in menopause symptom relief

2003

View full text Add to dashboard Cite

show abstract

“…Although C. racemosa has long been assumed to contain phytoestrogenic isoflavones, this could not be confirmed in either plant specimen from 13 different geographical locations nor in commercially available extracts [4]. Short term animal experiments have been conducted without being able to confirm estrogenic effects [5]. More recent in vitro experiments suggest antiestrogenic rather than estrogenic properties [6].…”

Section: Introductionmentioning

confidence: 96%

No estrogen-like effects of an isopropanolic extract of Rhizoma Cimicifugae racemosae on uterus and vena cava of rats after 17 day treatment

Kretzschmar

Nisslein

Zierau

et al. 2005

The Journal of Steroid Biochemistry and Molecular Biology

View full text Add to dashboard Cite

“…Thus, the compliance of patients for HRT decreases. Experiments in rodents as well as clinical studies in postmenopausal women demonstrated that CR extracts do not have uterotrophic effects [14,15], which was the basis for the assumption that they do not contain estrogenic compounds [16]. Yet, in ovariectomized rats, the aqueous/ethanolic extract BNO 1055 exerted estrogenic effects in the hypothalamus, in the bone and in the vagina (Wuttke et al, and Seidlová-Wuttke et al, this volume).…”

Section: Introductionmentioning

confidence: 99%

The Cimicifuga preparation BNO 1055 vs. conjugated estrogens in a double-blind placebo-controlled study: effects on menopause symptoms and bone markers

2003

View full text Add to dashboard Cite

Objectives: In the present study, therapeutic effects of the Cimicifuga racemosa preparation CR BNO 1055 (Klimadynon † /Menofem † ) on climacteric complaints, bone metabolism and endometrium will be compared with those of conjugated estrogens (CE) and placebo. The question whether CR BNO 1055 contains substances with selective estrogen receptor modulator (SERM) activity will be investigated. Methods: Sixty-two evaluable postmenopausal women were included in the double-blind, randomized, multicentre study, and treated either with CR BNO 1055 (daily dose corresponding to 40 mg herbal drug), 0.6 mg CE, or matching placebo, for 3 months. Menopausal symptoms were assessed by the menopause rating scale (MRS) and a diary. Levels of CrossLaps (marker of bone degradation) were determined by ELECSYS system and bone-specific alkaline phosphatase (marker of bone formation) by an enzymatic assay. Endometrial thickness was measured via transvaginal ultrasound; vaginal cytology was also studied. The primary efficacy criterion was the change from baseline to end point in the MRS. Change from baseline was analyzed for the secondary variables too. Results: CR BNO 1055 proved to be equipotent to CE and superior to placebo in reducing climacteric complaints. Under both preparations, beneficial effects on bone metabolism have been observed in the serum. CR BNO 1055 had no effect on endometrial thickness, which was significantly increased by CE. Vaginal superficial cells were increased under CE and CR BNO 1055 treatment. Conclusion: The results concerning climacteric complaints and on bone metabolism indicate an equipotent effect of CR BNO 1055 in comparison to 0.6 mg CE per day. It is proposed that CR BNO 1055 contains substances with SERM activity, i.e. with desired effects in the brain/ hypothalamus, in the bone and in the vagina, but without exerting uterotrophic effects. #

show abstract

Cimicifuga and Melbrosia lack oestrogenic effects in mice and rats

Cited by 79 publications

References 4 publications

Critical evaluation of the safety of Cimicifuga racemosa in menopause symptom relief

Critical evaluation of the safety of Cimicifuga racemosa in menopause symptom relief

No estrogen-like effects of an isopropanolic extract of Rhizoma Cimicifugae racemosae on uterus and vena cava of rats after 17 day treatment

The Cimicifuga preparation BNO 1055 vs. conjugated estrogens in a double-blind placebo-controlled study: effects on menopause symptoms and bone markers

Contact Info

Product

Resources

About